Compass Therapeutics (CMPX) vs Yarrow Bioscience (YARW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Yarrow Bioscience (YARW) has outperformed Compass Therapeutics (CMPX) over the past year, losing 7.5% versus a loss of 71.7%. Over five years, CMPX leads with a -68.2% price change compared with -98.3% for YARW. Compass Therapeutics is the larger company by market cap ($183.7 million vs $174.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | YARW |
|---|---|---|
| Share price | $1.02 | $18.78 |
| Market cap | $183.69M | $174.69M |
| 1-day change | +2.19% | +0.24% |
| YTD return | -81.01% | -35.26% |
| 1-year return | -71.75% | -7.51% |
| 5-year return | -68.22% | -98.29% |
| EPS (TTM) | $-0.39 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $46.95 |
| 52-week low | $0.829 | $16.05 |
| Distance from 52-week high | -85.17% | -60.01% |
| Analyst consensus | buy | none |
| Avg. price target upside | +434.31% | +203.60% |
| Average volume | 4.08M | 87.51K |
| Shares outstanding | 180.09M | 9.30M |
| Employees | 39 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- YARW has outperformed CMPX by 64.2 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Yarrow Bioscience
YARW stock →Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
CMPX vs YARW FAQ
Which is bigger, Compass Therapeutics or Yarrow Bioscience?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $183.69M compared with $174.69M for Yarrow Bioscience (YARW).
Which stock has performed better over the past year, CMPX or YARW?
YARW returned -7.51% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Yarrow Bioscience in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Compass Therapeutics and Biotechnology: Pharmaceutical Preparations for Yarrow Bioscience.